Rhonda L Bitting

Other · February 26, 2024 miRNAs detected at baseline, after three cycles, and after six cycles of treatment in the urine (left) and plasma (right), separated by responders (CR+PR, solid circles) versus nonresponders (SD+PD, open circles). Plot is mean value and er ... Full text Cite

TABLE 2 from Low-dose Paclitaxel with Pembrolizumab Enhances Clinical and Immunologic Responses in Platinum-refractory Urothelial Carcinoma

Other · February 26, 2024 All grade 3 or higher treatment-related AEs for subjects receiving at least one dose of combination therapy. Grade 2 treatment-related AES are included if >10% frequency ... Full text Cite

Data from Low-dose Paclitaxel with Pembrolizumab Enhances Clinical and Immunologic Responses in Platinum-refractory Urothelial Carcinoma

Other · February 26, 2024 <div>AbstractPurpose:Single-agent checkpoint inhibition is effective in a minority of patients with platinum-refractory urothelial carcinoma; therefore, the efficacy of combining low-dose paclitaxel with pembrolizumab was tested.< ... Full text Cite

Data from Low-dose Paclitaxel with Pembrolizumab Enhances Clinical and Immunologic Responses in Platinum-refractory Urothelial Carcinoma

Supplementary table S1 from Low-dose Paclitaxel with Pembrolizumab Enhances Clinical and Immunologic Responses in Platinum-refractory Urothelial Carcinoma

Other · February 26, 2024 MicroRNA levels are shown in responders and non-responders at baseline, after 3 cycles, and after 6 cycles of treatment. P-values suggest there is a trend toward differences in plasma miR 20a, miR 21, miR 125, miR 181, and miR 223 between ... Full text Cite

FIGURE 2 from Low-dose Paclitaxel with Pembrolizumab Enhances Clinical and Immunologic Responses in Platinum-refractory Urothelial Carcinoma

Other · February 26, 2024 The left panels show the number of CD4+ T cells (top) and CD8+ T cells (bottom) over time, separated by responders (CR+PR, solid circles) versus nonresponders (SD+PD, open circles). The right p ... Full text Cite

Supplementary figure S1 from Low-dose Paclitaxel with Pembrolizumab Enhances Clinical and Immunologic Responses in Platinum-refractory Urothelial Carcinoma

Other · February 26, 2024 The study design illustrated here shows the treatment phase with combination paclitaxel and pembrolizumab, followed by maintenance pembrolizumab if disease is stable or improved after 6 months of combination therapy. ... Full text Cite

Supplementary figure S1 from Low-dose Paclitaxel with Pembrolizumab Enhances Clinical and Immunologic Responses in Platinum-refractory Urothelial Carcinoma

TABLE 4 from Low-dose Paclitaxel with Pembrolizumab Enhances Clinical and Immunologic Responses in Platinum-refractory Urothelial Carcinoma

Other · February 26, 2024 Tissue PD-L1 status ... Full text Cite

TABLE 1 from Low-dose Paclitaxel with Pembrolizumab Enhances Clinical and Immunologic Responses in Platinum-refractory Urothelial Carcinoma

Other · February 26, 2024 Patient demographics and characteristics ... Full text Cite

TABLE 3 from Low-dose Paclitaxel with Pembrolizumab Enhances Clinical and Immunologic Responses in Platinum-refractory Urothelial Carcinoma

Other · February 26, 2024 Overall response rate for all participants receiving at least one cycle of treatment and for all patients evaluable by imaging ... Full text Cite